Mangoceuticals (MGRX) Accumulated Expenses (2022 - 2026)

Mangoceuticals (MGRX) has 5 years of Accumulated Expenses data on file, last reported at $3297.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses changed N/A year-over-year to $3297.0; the trailing twelve-month figure through Mar 2026 stood at $3297.0 (changed N/A YoY), and the FY2025 full-year result was $9421.0, changed N/A from the prior year.
• Accumulated Expenses fell to $3297.0 in Q1 2026, from $9421.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $9421.0 in Q4 2025 to a low of $2717.0 in Q4 2022.
• A 5-year average of $5556.8 and a median of $5133.5 in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 142.73% in 2023 and tumbled 36.57% in 2025, its largest moves.
• Tracing MGRX's Accumulated Expenses over 5 years: stood at $2717.0 in 2022, then surged by 142.73% to $6595.0 in 2023, then dropped by 15.39% to $5580.0 in 2024, then surged by 68.84% to $9421.0 in 2025, then tumbled by 65.0% to $3297.0 in 2026.
• Business Quant data shows MGRX's Accumulated Expenses at $3297.0 in Q1 2026, $9421.0 in Q4 2025, and $4460.0 in Q3 2025.